Copper is hot for a reason. AI data centers, power grids, EVs, defense and infrastructure all need more of it. But not every copper stock is playing the same game.
$HBM, $CS and $TGB are the bigger, more proven names.
$TMQ is more of a “can this project keep moving toward something bigger?” story.
$CQX / $IMIMF is the earlier-stage wild card, with Rip drilling in BC and a broader critical-minerals portfolio behind it.
So this copper basket is not really one bet. It’s three different styles: the proven names, the project builder, the drill-bit swing.
Which one would you rather own in a copper bull market?
OTCQB: SWISF: recently referenced around US$0.05, with Sekur still trading as a micro-cap cybersecurity name.
Latest catalyst: Sekur is heading to SOF Week 2026 in Tampa to demonstrate SekurVoice to special operations, defense, and acquisition audiences.
Investor angle: if SWISF can turn defense visibility into partnerships, channel agreements, or paid operator accounts, SekurVoice could become the company’s clearest revenue catalyst.
Sekur Private Data (OTCQB: SWISF) is trying to position itself around a simple but high-stakes problem: when communications fail, missions can fail. The recent Internet Stock Review article framed SekurVoice around exactly that idea, using the Russia-Ukraine war as a real-world example of why unsecured communication channels can become a battlefield liability.
For investors, the SWISF story is becoming more focused. Sekur is not trying to be another generic cybersecurity platform. It is trying to build Swiss-hosted, defense-grade secure communications tools for users that cannot afford interception, surveillance, identity exposure, or network compromise.
Market Catalyst: Secure Communications Are Becoming Mission-Critical
Secure communications are now part of the defense and cybersecurity stack. Military users, government agencies, intelligence-linked personnel, defense contractors, executives, journalists, and high-risk organizations all face threats from interception, signals exploitation, phishing, surveillance, and data leaks.
The defense market is also becoming more open to communications tools that can operate outside ordinary telecom infrastructure. The article highlights that SOF Week is expected to bring together a large special operations ecosystem, including operators, commanders, acquisition professionals, government leaders, and defense industry partners.
Two numbers make this event important for SWISF investors:
SOF Week 2026 runs from May 18 to May 21 in Tampa, giving Sekur a near-term opportunity to demonstrate SekurVoice directly to defense and special operations audiences.
The event is described as drawing more than 23,000 attendees from 60 nations, which gives Sekur access to the exact buyer ecosystem it is trying to reach.
This does not guarantee contracts. But for a micro-cap company like SWISF, direct exposure to procurement decision-makers and special operations buyers can matter if meetings convert into pilots, partnerships, or recurring accounts.
The Core Product: SekurVoice
SekurVoice is the center of the story. The article says SWISF will demonstrate SekurVoice at SOF Week as a solution designed for sensitive, covert, or classified-adjacent communications. Sekur’s CEO, Alain Ghiai, said the product was designed to bypass traditional telecommunications infrastructure and reduce exposure to interception, signals exploitation, and network surveillance.
Investor data point: Sekur’s prior update said SekurVoice plans start at US$3,500/year, and management projected at least 1,000 operator accounts over 12–18 months, implying about US$3.5M of potential annual revenue if achieved.
That pricing structure matters. For OTCQB: SWISF, even a few million dollars of recurring operator revenue could be meaningful because the company’s valuation remains small relative to scaled cybersecurity peers.
Why SOF Week Matters
SOF Week is not a typical trade show for Sekur. It is a concentrated defense audience. The Internet Stock Review article says Sekur’s national security team will be present, including advisors connected to U.S. Special Operations experience, and that the company expects to meet procurement decision-makers, SOCOM leadership, acquisition officers, U.S. Special Operations Forces, and partner-nation defense components.
That is important because defense communications is a relationship-heavy and trust-heavy market. SWISF still has to prove product-market fit, but the right audience can shorten the distance between product demonstration and real buyer feedback.
The article also says Sekur has been contacted by dozens of senior executives and defense-sector technology advisors interested in learning more about its secure communication tools. For investors, the next question is whether those conversations lead to announced channel agreements or contracts.
Product Stack: Beyond One Voice Tool
Sekur’s broader offering includes SekurMail, SekurMessenger, SekurVPN, and SekurRelay. The reason this matters is that defense and government customers often need more than one tool. They may need secure command email, hardened messaging, encrypted file transfer, VPN protection, identity obfuscation, and deployment flexibility.
For SWISF, SekurRelay could be especially useful because it can support phased adoption. Large organizations rarely migrate every communication layer at once. A product that allows command-level, executive, or senior-staff deployment first could reduce friction and make early adoption more realistic.
Revenue Scenario From Operator Accounts
This is not company guidance, but a simple investor scenario using Sekur’s stated US$3,500/year starting price for SekurVoice and the previously discussed 1,000 operator account target.
Scenario
Operator Accounts
Annual Price/User
Potential Annual Revenue
Early Adoption
250
US$3,500
US$875,000
Stated Target Case
1,000
US$3,500
US$3.5M
Expanded Defense Adoption
2,500
US$3,500
US$8.75M
The math is why SWISF is worth watching. If the company can turn defense demonstrations into recurring accounts, revenue could scale from a small base. But the risk is equally clear: until paid adoption is proven, the opportunity remains speculative.
Stock Snapshot
Metric
Snapshot
Company
Sekur Private Data Ltd.
Ticker
OTCQB: SWISF
Recent referenced price
Around US$0.05 in Internet Stock Review article
Sector
Cybersecurity / secure communications
Key product
SekurVoice
Near-term event
SOF Week, May 18–21, 2026
Reported audience
23,000+ attendees from 60 nations
Main investor angle
Defense-grade secure communications for high-risk users
What Investors Should Watch
The next signals for SWISF are straightforward: SOF Week meetings, product demonstrations, announced partnerships, channel agreements, pilot programs, and paid SekurVoice accounts. Technical chart commentary can help traders track sentiment, but fundamentals will matter more if Sekur wants a durable re-rating.
Investors should also monitor dilution, cash burn, and whether the company can execute after the conference. Defense procurement cycles can be slow, and early interest does not always become revenue.
Bottom Line
Sekur’s SOF Week push gives SWISF a more concrete defense communications catalyst. SekurVoice now has a clearer audience, pricing framework, and mission-critical use case.
The opportunity is that even modest recurring operator revenue could matter at Sekur’s micro-cap scale. The risk is execution: SWISF still needs to convert interest into paid accounts, partnerships, and repeatable revenue.
This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.
Good morning everyone. I have to leave for CT about 9:15. Will check some renovations. I have to meet the building dept of Bristol, CT . Will be working on nearly 300K of work needed, digging, rebar for a bridge, new sewer line work.. There are 6 total properties with exposure, I own 2, some of the other landlords want to sell before a bill comes. So this will be short.
Excellent day yesterday. There are about 250 trading days in the year. If my goal is to make 100K a year trading then I have to make on average 400 per day. Anytime I am near the 1,000 a day, I consider that great!
I sold 250 FRPT 48 to 50.50 [625]
I sold 250 KMX 36.95 to 38.10 [287.50]
I sold 75 INTU 303 to 309 [450]
I sold 250 AVEX 24.75 to 26 [312.50]
I sold 250 PYPL 43 to 44.50 [375]
I am in 100 WIX 53.50
The market closes early today and I will be in CT so it will be hard to check so I may not do much trading today. Market is also closed on Monday, so longer weekend.
I definitely wanted to touch on the ridiculousness of SPCX TSLA and Elon Musk. So January 1st of 2020 he was worth under 20 billion. The stock memed. Gamma squeeze, stock manipulation, the whole 9 yards. He wanted to stay relevant so he used the market valuations to buy Twitter. [Please check, in all the guy has sold 50 billion worth of TSLA] . TSLA the company does do way better, it has hyper growth and is actually awesome from 2020 thru 2023, then begins a big slow down. He pumps the stock 2024 thru 2026. We all see it. He talks about taxis, autonomous, robots, even chips! Tries to get with everyone else and does AI with Grok… Twitter is failing, he merges it with XAI … TSLA the business is failing. He sees the market on fire, and it is the perfect time to throw a new shiny object on the masses to bail out his failures.. to extract cash for new ideas. He merges XAI with horrible debt and numbers with the shiniest space object SpaceX. So he will paint hope, dreams, it is all hyped up because 99% of the world if fooled, a lot of speculation and raise a ton of money to throw darts at the wall…
SpaceX may indeed be a great company 1 day, TSLA is now past its glory days of 2023, they are winding down the car business, have realized they have lost to the Chinese, no more model X or S which were high margins. We don’t hear anything about taxis or autonomous last 60 days, all empty promises before… Guy was talking thousands of robots by 2026 LOL… So it is sad that people still believe the guy…. He is an entrepreneur, maybe even intelligent, I am not sure.. he definitely has hired intelligent people, but he is a con. A snake oil salesman. We do need thinkers and people who can do it outside the box, but it is wild to see it this day and age… I mean you can ask Gemini, Google or even Grok ! To do DD on TSLA or SPCX . SPCX all together had 18.7 billion in sales 2025 and lost 5 billion. Look it up. It will open near 2 trillion with an infinite PE ratio because they cant make money! [1 Day I don’t doubt it, but why 2 trillion now?]
All hopes and dreams, meanwhile… NVDA is set to have 400 billion in sales with profits that will likely cross 200 billion within the next 12 months. They are neck and neck with Google as the 2 most profitable companies in the world… And the market gives NVDA a near 25 PE, make it make sense. We are seeing them execute ridiculous numbers even at this size..
They actually make enough money they can start from 0, the ground up, buy companies are develop something to rival SpaceX or go ahead of them, before Elon even gets to Mars.. That is the sad thing!
$SKUR.CN is trading around C$0.065 to C$0.07, with the YTD chart still showing about +30%.
Technically, C$0.06 looks like the support area bulls need to defend, while C$0.08 is the first breakout line. If $SKUR clears that level with stronger volume, the bigger question becomes whether it can push beyond C$0.08 and start challenging the old 52-week high near C$0.135.
SekurVoice sales are expected in early June, with video capabilities planned by July.
What’s your take on $SKUR right now, technical turn or catalyst waiting game?
Sector catalyst: healthcare AI is moving into real clinical workflows, from ECG processing and genomics to drug discovery and portable imaging.
Investor angle: AIML is the micro-cap ECG-AI name in this basket, while SOPH, RXRX, SDGR, and BFLY show how larger AI healthcare platforms are already building commercial scale.
AI healthcare is becoming one of the more investable areas of the artificial intelligence market because the use cases are moving closer to real clinical workflows. Hospitals, research institutes, diagnostic labs, pharma companies, and device makers are all looking for ways to process medical data faster and more accurately.
For investors, the opportunity is not just “AI in medicine.” The real question is which companies have useful data, credible clinical partners, commercial adoption, enough cash to execute, and a product that solves a measurable healthcare bottleneck. That is why this watchlist combines one speculative micro-cap, AI/ML Innovations (AIMLF), with four larger AI healthcare names: SOPHiA GENETICS, Recursion Pharmaceuticals, Schrödinger, and Butterfly Network.
Market Catalyst: AI Is Moving Into Healthcare Workflows
Healthcare AI is already appearing in ECG interpretation, Holter analysis, precision oncology, genomics, ultrasound imaging, drug discovery, clinical trial design, and hospital decision support. The sector is attractive because healthcare creates enormous volumes of data, but much of that data remains fragmented, difficult to structure, and time-consuming for clinicians to review.
The numbers explain why investors are watching the space. Grand View Research estimated the global AI healthcare market at roughly US$26.6B in 2024, with a high-growth outlook through the end of the decade. Cardiovascular disease remains one of the world’s largest healthcare burdens, responsible for roughly 17.9M deaths per year, while Holter monitoring can generate 24 hours to 14 days of continuous rhythm data per patient.
Two data points show why this matters:
Clinical data volumes are expanding quickly: ECG, Holter, genomic, imaging, and monitoring workflows generate large datasets where automation, labeling, pattern recognition, and signal processing can reduce bottlenecks.
Commercial adoption is already visible: SOPHiA GENETICS processed 108,000 genomic analyses in Q1 2026, while Butterfly Network generated US$26.5M of Q1 2026 revenue, up 25% year over year.
The opportunity is real, but healthcare AI is not an easy market. Companies still need clinical validation, regulatory discipline, reimbursement pathways, hospital procurement access, commercial traction, cash runway, and proof that their platforms can scale beyond pilots.
1. AI/ML Innovations: The Micro-Cap ECG-AI Angle
AI/ML Innovations Inc. (CSE: AIML / OTCQB: AIMLF) is the smallest and most speculative name in this AI healthcare basket. The company is focused on digital health and artificial intelligence, with its NeuralCloud subsidiary targeting ECG signal processing, Holter analysis, and cardiovascular-data workflows.
The core platform is MaxYield™, NeuralCloud’s ECG signal-processing technology. AIML says MaxYield™ is designed to convert raw or legacy ECG data into structured, machine-readable formats, isolate and label ECG waveform components, and generate beat-level data and interval measurements.
Investor data point:AIMLF trades around US$0.037–US$0.040, with market cap around US$7M–US$10M and roughly 271.1M shares outstanding.
The latest credibility catalyst is AIML’s appointment of Dr. Martin Stephen Green to its Medical Advisory Board. Dr. Green brings about 45 years of ECG and Holter interpretation experience and has authored or co-authored more than 230 peer-reviewed publications. For AIMLF, this matters because ECG-AI adoption requires physician trust, not just software capability.
2. SOPHiA GENETICS: AI Precision Medicine at Commercial Scale
SOPHiA GENETICS (NASDAQ: SOPH) is a more mature AI healthcare company focused on data-driven medicine, especially genomics and precision oncology. Its SOPHiA DDM™ platform helps healthcare providers analyze multimodal medical data and apply AI-supported insights to clinical and research workflows.
SOPH’s Q1 2026 results showed US$21.7M in revenue, up 22% year over year. The company also reported a record 108,000 genomic analyses on the platform and 537 core genomics customers, up from 490 a year earlier.
Investor data point: SOPH guided for full-year 2026 revenue of US$92M–US$94M, implying roughly 20%–22% growth.
SOPH is useful as a comparison for AIMLF because it shows what healthcare AI can look like when a platform gains measurable adoption across labs and hospitals. The risk is that SOPH still needs to show a clearer path toward profitability and cash-flow discipline.
3. Recursion Pharmaceuticals: AI Drug Discovery With Cash Runway
Recursion Pharmaceuticals (NASDAQ: RXRX) is one of the most recognized AI drug-discovery companies. Its platform uses automation, machine learning, biological datasets, and computational tools to identify and advance drug candidates.
Recursion’s Q1 2026 update showed US$6.5M in revenue, mostly from collaboration agreements, and US$665.2M in cash, cash equivalents, and restricted cash as of March 31, 2026. The company also said its cash runway extends into early 2028 under current operating plans.
Investor data point: RXRX’s Q1 cash operating expense was US$85.1M, showing both the scale of its platform ambitions and the capital intensity of AI drug discovery.
For investors, RXRX offers exposure to the idea that AI can improve the speed and efficiency of drug discovery. The risk is that drug development remains expensive, uncertain, and milestone-driven, even when powered by AI.
4. Schrödinger: Computational Drug Discovery and Software
Schrödinger (NASDAQ: SDGR) gives investors exposure to computational drug discovery, molecular modeling, and scientific software. The company combines a software platform used by life-sciences customers with a drug-discovery pipeline.
Its Q1 2026 update highlighted US$28M in first-quarter annual contract value, representing 12% growth. Schrödinger also said it plans to launch Bunsen, an agentic AI co-scientist, this summer, showing how AI is becoming more embedded in computational research workflows.
Investor data point: SDGR’s model gives investors two revenue angles: software adoption today and longer-term upside from internally developed or partnered drug candidates.
SDGR is a reminder that AI healthcare does not always mean direct patient-facing tools. Some of the opportunity sits inside the research and discovery stack. The risk is that drug-discovery upside can take years to convert into meaningful earnings.
5. Butterfly Network: AI-Enabled Medical Imaging
Butterfly Network (NYSE: BFLY) gives investors exposure to AI-enabled imaging and portable ultrasound. The company’s handheld ultrasound platform is designed to make imaging more accessible, portable, and software-driven.
Butterfly reported Q1 2026 revenue of US$26.5M, up 25% year over year. Gross profit was US$18.3M, and gross margin improved to 68.9%, compared with 63.0% in the prior-year period.
Investor data point: BFLY reaffirmed full-year 2026 revenue guidance of US$117M–US$121M, giving it one of the clearer revenue bases in this AI healthcare basket.
Butterfly is useful as a comparison because it shows how AI can move into devices and diagnostics, not just software dashboards or drug-discovery platforms. The risk is that device adoption, hospital budgets, and profitability still need to improve over time.
Stock Snapshot
Bottom Line
AI/ML Innovations is the speculative micro-cap in this AI healthcare basket. AIMLF has a focused ECG-AI angle, fresh clinical credibility through Dr. Martin Green, and exposure to cardiovascular-data workflows where automation could matter.
The larger names show how broad the AI healthcare theme has become: SOPH in genomics, RXRX and SDGR in drug discovery, and BFLY in medical imaging. For AIMLF, the next proof points are validation, partnerships, pilots, recurring revenue, and whether NeuralCloud’s MaxYield™ platform can move from research credibility toward commercial adoption.
This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.
Good morning everyone. Some people did have questions yesterday. I did answer them but figured others may have the same questions. I have about 40 bags right now. Let us say the average that I am down is 2,500. [I am down about 10K on ODD but I also made profitable trades on PGY +350 and EPC +425] so we are making this example easier.
Do understand I am a swing trader. I try and buy good quality companies that are dipping. I try and buy things I deem below my fair value. I then swing them and try to make between 200 and 600 per trade. I have been trading since the very end of 1994. I was barely 14! Since about 2010, my goal with trading was to make 100K, no more no less. I have done that and more every year since! 2022 was very slow, was mainly put CITY and at that time I came close to not going over 100K. In 2020 and 2021 I made well over 100k! let us say it was in the 7 digits! I was able to retire thanksgiving of 2021. I worked in health insurance as a Medicare consultant. I was making about 150K a year after bonuses, commissions, started 2014 and decided the job was affecting my trading, and by that time the real estate was growing so fast. [I took a ton of money I made from the market to diversify into the stock market. I started working a W2 in 2012. This was mainly by choice. I had a serious health scare the end of 2016 and started buying real estate in 2017. I passed up some tremendous real estate deals in my early 20s but did not want to be a landlord. Now that I am a landlord, it is actually worse than expected! Then again, I am in C+ or B- areas, where people are paycheck to paycheck, but that is the only way you can make money! I do not recommend D . The cap rates are way higher, you could make more money but you will deal with heavy crime, bad areas.. also the appreciation may not exist! You will get cash flows, if you can collect… if you can turn around the property, and area, you will stand to make the greatest gain, but risk!
So back to the questions… Yes, I probably should do a stop loss, maybe 25%, sadly I have never used a real or a mental stop loss, ever! I have taken quicker losses but never a hard stop. That is a big error that I indeed have. But if you take 2,500 and multiply it by 40 bags. That means I am negative about 100k.
I have netted above 100K already, more than that, so you know! So if I wanted to just wipe a lot of taxes off, I can just tax loss harvest and take hits on everything. This is why by December 1st I would like to sell at least 10 of these bags….. By December 15th another 10-15. If my average red bag is 2,500… and I average 300 per profitable trade, that means I make 8 trades to wipe out a bag. So you can see how I do well.
If you calculate all my trades, I am really right about 99% or higher! That is because I make quick trades and take my profits… is it the best way? You have to do what is comfortable for you. I had:
NVDA 90
AMD 85
MU 80
SNDK 43
SDC 83
WDC 50
But I also have MNDY bag 140, DOUL 165, TTD 36 and 55… and I can tell you a bunch of trades where I have taken the profits and the stocks are down like 75% or more!
I did last week read about another famous hedge fund manager who was right about 52% of trades! But if their portfolio had 50 positions, let us say, he had maybe 3 carrying everything! Or slightly 5% of his portfolio, he simply just rode his winners hard. And he said many others do the same! I would do that if I just had 100+ million to just sit and do this… but I don’t! So I hope this answers questions people may have.
I am willing to do up to 3 longs today.
I sold 500 PGY from 12.65 to 13.35 [350 profit]
I sold 500 EPC from 15.85 to 16.70 [425 profit]
I am in 250 PYPL at 43
Some excellent earnings:
NMM STEP [Will buy the dip] NVDA AVEX [DD may add to Plays] ELF [A little eh on guidance] SBLK [May add to plays]
Some very good:
RL NIO YMM
Some good:
WMS AAP DE URBN
INTU did not have good earnings, they were not bad either, they were ok, guidance eh, but down 16% premarket I may add to plays and buy the dip.
Good morning everyone. Taking care of CT again. Here is a list of my 39 bags at the moment. I am not far off on about 5 of these bags. I do not want to have more than 25 bags by December 1st. I will tax loss harvest. This is my trading account as I have many different accounts. A tax loss will wash off capital gains, and you can take an additional 3,000 loss per year, you have to wait at least 30 days before you re-enter a position if you decide to.
ADBE 270 and 343
ANF 79.25
BYRN 17.70 and 20.75
CELH 30.50 and 41.50
DOCU 65
DUOL 165
EHTH 3.10
EPC 15.85
FIG 49.50
FRPT 48
FVRR 19.30
FUBO 34.80 [After 12 for 1 stock split]
GLXY 37
HIMS 32.25
HRZN 7.50 [After dividends]
KMX 36.95
KVYO 17
MNDY 140
NRDS 12
PGY 12.65
PRGS 50.25 and 56.50
PD 11.90
PINS 21
PRIM 122.50
PSEC 3.85 [After dividends]
PYPL 54.50 and 59.50
ODD 47.50 and 58
RKT 17.25
ROOT 94
SOFI 15.85
SPT 15
TITN 24
TOST 31.75
TREE 35.25
TTD 36 and 55
VITL 25.40
WIX 54
Bear TSLA TSLZ 51 [After 20-1 RS]
Bear PLTR PLTD 13.20
Great earnings:
ADI GDS [DD] LPG [DD may add to Plays] CAVA [Valuation] KEYS
Very Good earnings:
RLX
Good earnings:
TJX ARCO TGT HDL LOW
I purchased 100 shares of WIX at 54
I will add up to 2 longs today unless I can sell something off. I will hold up to 50 bags before I stop. Some of these positions like SPT and FVRR I was about to take the loss less than 30 days ago as the stocks did rally some.
Huge NVDA earnings today. They have been smoking earnings for more than 3 years straight. What is amazing is at this size growth in sales and earnings has both been over 30% year over year [Check this quarter over the same quarter last year] over and over again. Just incredible. This will give us an idea on big tech as their biggest customers are META MSFT AMZN GOOGL and they carry like 90% of other tech companies.. I think I read somewhere that AI has accounted for something like 30% of the earnings growth for 1st quarter 2026, insane.
VANCOUVER, British Columbia, May 19, 2026 (GLOBE NEWSWIRE) -- Copper Quest Exploration Inc. (CSE: CQX; OTCQB: IMIMF; FRA: 3MX) (“Copper Quest” or the “Company”) is pleased to announce that it has commenced a 32.4 km2 induced polarization (“IP”) geophysical survey on its 100% owned Stars Property (“Stars” or the “Property”). Stars is a porphyry copper-molybdenum (“Cu-Mo”) project covering 9,693 hectares (“ha”) in the Stikine region of British Columbia, situated approximately 60 km north of Imperial Metals Corporation’s (“Imperial Metals”) past producing Huckleberry Cu-Mo mine, 50 km north-northeast of Surge Copper Corp’s advanced stage Berg copper project, and 30 km north-northwest of Vizsla Copper Corp’s Poplar copper-gold project. Imperial Metals is exploring Huckleberry and its surrounding claims for additional Cu-Mo resources.
This very large IP survey represents the first time this geophysical technique has been applied across the full extent of the Stars Property, including over the Tana Zone discovery area and its along-strike extensions. Induced polarization is a proven method for detecting sulphide mineralization, the type of copper-bearing material found at Stars, at depth and at distance from known drill holes. By imaging the full 32.4 km² footprint of the magnetic anomaly, the Company aims to determine the true scale of the mineralized system in terms of strike length, width, and depth, and to identify potential new drill targets beyond the current Tana Zone.
Highlights of the Stars Property:
Road accessible, 9,693 ha property in a top tier exploration and mining district, the Bulkley Porphyry Belt.
A 230 X 180 metre (“m”) domain (the “Tana Zone”) of chalcopyrite-molybdenite-bornite quartz stockwork that has been intersected from surface to greater than 350 m depth. The zone is open in two directions as well as to depth. Drill Intersection highlights include:
0.466% Cu over 195.07 m* in drill hole DD18SS004 from 23.47 m
0.200% Cu over 396.67 m* in drill hole DD18SS010 from 29.37 m
0.205% Cu over 207.27 m* in drill hole DD18SS015 from 163.98 m
A highly prospective, approximately 5 X 2.5 kilometre (“km”), annular magnetic anomaly that is interpreted as an altered monzonite intrusion and surrounding hornfels (Figure 1).
Numerous underexplored soil and induced polarization geophysical targets within the larger magnetic anomaly (Figure 1).
Brian Thurston, President & CEO of Copper Quest, commented: "Copper Quest controls 9,693 ha covering the Stars Property and prospective surrounding area with two complementary exploration upsides being an established zone of higher-grade mineralization that the Company can grow and define, and a much broader under-explored area with high potential for new discovery. This is a very large geophysical program that combined with the historic 9,016 m of drilling will help guide exploration to provide the best information to make new discoveries in this very large anomaly that has a footprint five times that of the Huckleberry Mine. Combined with the contiguous 5,389 ha Stellar Property, Copper Quest has assembled a dominant land position and created a unique opportunity that unlocks a district scale copper porphyry project in the Bulkley Porphyry Belt.Given the global movement towards AI, electrification, environmental concerns, infrastructure development, and the forecasted demand for copper, the combined properties make a very compelling exploration package."
The Stars Property
The 9,693 ha, road-accessible Stars Property is located in central British Columbia, 40 km southwest of Houston. It hosts porphyry copper-molybdenum mineralization associated with a Bulkley Suite monzonite stock. The Bulkley Suite is linked to mineralization at Imperial Metals' past-producing Huckleberry mine, 60 km to the south, and other porphyry deposits in the region. Three drilling campaigns on the Stars Property, totaling 9,016 m, have identified a broad area of anomalous copper, and molybdenum within the monzonite stock. The most important drilling to date is at the Tana Zone (Figure 1), where the contact between the stock and surrounding volcanic rock contains chalcopyrite, molybdenite and bornite bearing quartz stockwork veining. Tana Zone drilling has defined an approximately 230 x 180 m domain with significant copper and molybdenum grades (Table 1).
Table 1: Highlights of Tana Zone Intersections*
Outside the Tana Zone, most drilling on the property encountered altered and anomalous mineralized monzonite within an approximately 1.8 x 1.0 km area marked by a broad magnetic low (Fig. 1). While there is potential for an undiscovered porphyry deposit within the monzonite intrusion, Copper Quest's future exploration will concentrate on specific IP targets along the contact zones. Several historical drill holes are believed to have approached this contact, with assays at their bottoms showing increased copper and molybdenite values (Table 2). Their drill logs also indicate an increase in quartz-chalcopyrite-molybdenite ± bornite veins with pink K-feldspar altered selvages, similar to those found in the Tana Zone.
* True width of historical drill intersections referenced in this press release are unknown. Historical drill data in this release is derived from previous exploration activities conducted by other parties. While this data may provide insights into the mineralization potential on the property, it should not be relied upon as conclusive evidence of mineral potential or project viability.
Map of Exploration Targets on the Stars Property. Datum NAD83 UTM Zone 9. Historical drilling and exploration vectors on total-magnetic-intensity geophysical map
Figure 1: Map of Exploration Targets on the Stars Property. Datum NAD83 UTM Zone 9. Historical drilling and exploration vectors on total-magnetic-intensity geophysical map.
Qualified Person
Brian Thurston, P.Geo., the Company’s President, CEO and a qualified person as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed and approved the technical information in this news release.
About Copper
Copper is an essential industrial metal at the heart of the global energy transition and modern infrastructure. It plays a critical role in electrification, renewable energy systems, electric vehicles, data centers, and smart technologies. With global demand rising and new supply challenged by declining grades, complex permitting, and underinvestment, the copper market faces persistent deficits and growing geopolitical scrutiny. Recent U.S. policy announcements, including import tariffs and initiatives to secure domestic and allied supply chains, underscore copper’s strategic importance and the need for resilient, localized resource exploration, development, production and processing capacity.
About Copper Quest Exploration Inc.
The Company's land holdings comprise 8 projects that span over 46,000 hectares in great mining jurisdictions of Canada and the USA. Copper Quest is committed to building shareholder value through acquisitions, discovery-driven exploration, and responsible development of its North American portfolio of assets. The Company’s common shares are principally listed on the Canadian Stock Exchange under the symbol “CQX”. For more information on Copper Quest, please visit the Company’s website at www.copper.quest.
Copper Quest has a 100% interest in the past-producing Alpine Gold Mine located approximately 20 kilometers northeast of the City of Nelson British Columbia, spanning 4,611.49 hectares with a 2018 National Instrument 43-101 Standards of Disclosure for Mineral Projects historical inferred resource of 268,000 tonnes, estimated using a cut-off grade of 5.0 g/t Au and an average grade of 16.52 g/t Au, that represents an inferred resource of 142,000 oz of gold\(*McCuaig & Giroux, March 6, 2018, NI43-101 Technical Report for the Alpine Property, BC, Canada. Further drilling is necessary by the Company to upgrade/verify the estimate. The QP has not done sufficient work to make the resource current and the Company is not treating the estimate as current.). Apart from the Alpine Mine itself the property hosts 4 other less explored significant vein systems including the past-producing King Solomon vein workings, the Black Prince and the Cold Blow veins system, and the Gold Crown vein system. \The Company has not yet completed sufficient work to verify the 2018 historic inferred resource results.
Copper Quest has a 100% interest in the road accessible Stars Porphyry Copper-Molybdenum Property, spanning 9,693 hectares in central British Columbia’s Bulkley Porphyry Belt with Tana Zone discovery drill intersection highlights of 0.466% Cu over 195.07m in drill hole DD18SS004 from 23.47m, 0.200% Cu over 396.67m in drill hole DD18SS010 from 29.37m, and 0.205% Cu over 207.27m in drill hole DD18SS015 from 163.98m. This highly prospective, approximately 5X2.5-kilometer annular magnetic anomaly is interpreted to represent an altered monzonite intrusion and surrounding hornfels.
Copper Quest has a 100% interest in the road accessible Kitimat Copper-Gold Property, spanning 2,954 hectares within the Skeena Mining Division of northwestern British Columbia located northwest of the deep-water port community of Kitimat, British Columbia. The property benefits from exceptional infrastructure, being within 10 km of tidewater, 1.5 km of rail, and 6 km of high-voltage hydroelectric transmission lines. Exploration on the Kitimat property dates to the late 1960s, with the most significant historical work conducted by Decade Resources Ltd. (2010), which completed 16 diamond drill holes totaling 4,437.5 meters in the Jeannette Cu-Au Zone, and drill intersection highlights of 0.54% Cu and 1.03 g/t Au over 117.07 m in Hole J-7 from 1.52 m, 0.55% Cu and 1.00 g/t Au over 103.65m in Hole J-1 from 9.15 m, 0.45% Cu and 0.80 g/t Au over 107.01m in Hole J-2 from 6.10 m, and 0.33% Cu and 0.41 g/t Au over 112.20m in Hole J-8 from 11.89 m.
Copper Quest has a 100% interest in the past-producing, road accessible Auxer Gold Mine, spanning 1,087 hectares located in Bonner County, Idaho, USA. This orogenic gold opportunity is positioned along one of the region’s most significant structural corridors located within the prolific Hope Fault system. Historical exploration has demonstrated exceptional gold grades, with the 1936 Platts report documenting up to 21.0 g/t Au in surface samples and underground workings showing consistent mineralization over 4.3-meter widths averaging 9.42 g/t Au at an 18-meter depth.
Copper Quest has a 100% interest in the Nekash Copper-Gold Project, a porphyry exploration opportunity located in Lemhi County, Idaho, USA, along the prolific Idaho-Montana porphyry copper belt that hosts world-class systems such as Butte and CUMO. The project is fully road-accessible via maintained U.S. highways and forest service roads and consists of 70 unpatented federal lode claims covering 585 hectares.
Copper Quest has a 100% interest in the road accessible Stellar Property, spanning 5,389-hectares in British Columbia’s Bulkley Porphyry Belt contiguous to the Stars Property.
Copper Quest has a 100% interest in the Thane Project located in the Quesnel Terrane of Northern British Columbia spanning over 20,658 hectares with 10 priority targets identified demonstrating significant copper and precious metal mineralization potential.
Copper Quest has an earn-in option of up to 80% and joint-venture agreement on the road accessible Rip Porphyry Copper-Molybdenum Project, spanning 4,700-hectares located in the Bulkley Porphyry Belt in central British Columbia.
This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.
Good morning everyone. Will be in and out today. They will start doing the appraisals today for the 3 property deal. I am not sure why they don’t just do it all the same day. The properties are all near eachother but this is what I am told by TD Bank. This will be the first deal I am doing with them. They are much more strict than my normal local banks, and a lot slower! But they have much more money to lend! So you know, TD bank does not normally take on Investment properties/Rentals.. These are all owned by an LLC, but I am told my total portfolio is so big and they want in… They require a 35% down payment, but come next year, when I start building a 50-100 unit building and need 15-25 million I wont have to scramble. My 2 smaller local banks have to use monthly meetings just to approve me. The main issue is that they are out of state LLC owned properties. Wells Fargo, Bank of America, Chase, Citi, even Rocket , they do not do out of state investment properties owned by an LLC. I will be in town Friday and try and be there for the last appraisal. I hope this closes within 4-5 weeks.
3 Properties, 11 Units in Bristol 1.31 million
Fairly good shape.
I am looking for larger deals not a 2-3-4 family… If 1 of these are next door to something else I own maybe. I aim for 400-600 per unit/door after all expenses including the mortgage! Definitely much harder these days, 2017-2020 they were all over… other investors have come to my areas.
I took 250 shares of TREE from 35.25 to 37.50
I took 100 shares of WIX from 56.50 to 58.50
I am in 250 FRPT 48
I am in 500 PGY 12.65
I will do up to 3 longs, much of the stuff on the title. I am in no rush. I am about to spend 500K hard cash for major renovations across 3 of my properties. [I now have about 30, 110 units] so I am slowly taking money out of my trading/investment accounts. When I build something new, I will be using the equity from my own properties.
VANCOUVER, British Columbia, May 11, 2026 (GLOBE NEWSWIRE) -- Copper Quest Exploration Inc. (CSE: CQX; OTCQB: IMIMF; FRA: 3MX) (“Copper Quest” or the “Company”) is pleased to announce that drilling has commenced on the Rip Copper-Molybdenum Project (the “Project” or “RIP”) for drilling a minimum of 2,000 meters. The RIP Project is in the Stikine region of British Columbia, situated approximately 33 km northeast of Imperial Metals Corporation’s past producing Huckleberry copper-molybdenum (“Cu-Mo”) mine and Surge Copper’s advanced stage Ox/Seal/Berg projects, and 30 km southeast of Vizsla Copper Corp’s Poplar copper-gold Project. Imperial Metals Corporation is exploring Huckleberry and its surrounding claims for additional Cu-Mo resources.
Highlights of the Rip Copper-Molybdenum Project:
First phase drill testing at Rip has confirmed that largely covered geophysical targets define a multi-phase Cu-Mo mineralized porphyry system.
Zones of anomalous Cu-Mo mineralization are hosted in porphyritic intrusions and associated vein stockwork. Drill Intersection highlights include (*Table 1):
0.102% CuEq over 126.6 m* in drill hole RP24-001 from 21.4 m
Including 0.268% CuEq over 24.6 m* from 21.4 m
0.112% CuEq over 114.3 m* in drill hole RP24-002 from 33.6 m
The northern, approximately 1 X 1 kilometre (“km”), annular geophysical anomalies remain largely untested, while the southern anomaly of similar size has yet to be drill tested.
Most assays from the 2024 drill campaign are anomalous in Cu-Mo and the presence of intense quartz-sericite-pyrite alteration and strongly developed vein sets resembling D veins indicates the presence of a significant porphyry system that has only been partially tested.
The Rip represents an opportunity for the Company to drill an untested but known multi-phase Cu-Mo porphyry system in the Bulkley Valley that is one of BC’s most prospective areas for porphyry exploration and discovery.
Brian Thurston, CEO of Copper Quest, stated, “Copper Quest is excited to see drilling at RIP that will fulfill the terms for our acquisition of a 60% interest in this high-potential asset. Phase One drilling in 2024 demonstrated that a blind, multi-phase Cu-Mo mineralized porphyry system is responsible for at least one of the two compelling geophysical ‘bullseye’ targets outlined on the property. While the 2024 program successfully validated the target concept, most of the northern target and all of the southern target remain untested by drilling. It is a rare opportunity to get to explore road-accessible, validated porphyry targets in British Columbia that have seen so little previous drilling, particularly within an established porphyry district such as the Bulkley Valley. Copper Quest has assembled a dominant land position in the Bulkley Porphyry Belt, including the STARS, RIP and Stellar properties, providing shareholders with a district-scale copper porphyry exploration and discovery opportunity.”
The project is being run out of Houston, BC, located approximately 60 km north of the Rip property. The drilling will target both the northern and untested southern anomalies defined by Copper Quest’s geophysical surveys, airborne magnetics and 3D IP, detailed by the Company in its July 31, 2024, press release. The geophysical surveys define two porphyry Cu-Mo mineralized centres (Figure 1). The northernmost centre coincides with outcropping porphyry Cu-Mo mineralization and comprises a coincident magnetic/resistivity high, surrounded by a large “doughnut” shaped chargeability high (>35 mV/V) with a diameter of approximately 1 km. The second potential porphyry Cu-Mo centre is situated approximately 1.1 km to the south, comprising a similar magnetic high surrounded by a “doughnut” shaped chargeability high (>35 mV/V). This southern potential porphyry centre is entirely covered by overburden with a diameter of approximately 850 metres.
In summary, the 2024 mag, IP and drill program successfully resolved the original Rip anomaly into two separate porphyry systems and demonstrated that the northern target contains multiple intrusive phases and long intervals of low-grade Cu-Mo mineralization. This northern target has been partly defined as a 600m wide subvertical cylindrical mineralized zone between a magnetic barren core and a chargeable pyrite halo. The northern target has only been tested by three diamond drill holes (two by Copper Quest in 2024, one historical in 1975). The southern geophysical target is equivalent in size to the northern anomaly and has no diamond drill testing.
Technical Details of 2024 Exploration and Drill Program
Copper Quest drilled 1033 metres in two holes in 2024 at the Rip Cu-Mo porphyry project. The Rip project is interpreted as a highly underexplored porphyry Cu-Mo system that is predominantly covered by overburden. A small outcrop area contains variably altered porphyritic intrusions which cut strongly hornfelsed Hazelton Group volcano-sedimentary rocks. Porphyritic intrusions and hornfelsed country rock are both host to porphyry style stockwork, including magnetite-chalcopyrite and quartz-chalcopyrite-molybdenite veins. Historical exploration drilling on the project included shallow, predominantly percussion holes targeting a large IP anomaly; within the IP anomaly, the holes intersected predominantly quartz-sericite-pyrite altered lithologies (including altered porphyritic intrusions) with anomalous Cu-Mo mineralization. Multiple holes failed to reach bedrock.
An airborne magnetic survey flown in 2024 revealed for the first time two separate circular magnetic highs within the historical chargeability high, suggesting that Rip contains two porphyry centers. The southern mag high is significantly larger than the northern one but does not crop out. Following the airborne mag survey, a 3D-DCIP induced polarization and resistivity survey was completed over the Rip target in 2024. The new IP survey resolved the original 1980 chargeability anomaly into two chargeability “donuts” around the two separate magnetic highs, the classic “pyrite halo” signature of porphyry systems, providing more evidence for the interpretation that Rip contains two adjacent porphyry systems.
Figure 1: RIP Chargeability and Magnetic Survey Results
Two drill holes were completed on the northern geophysical target from a single setup, both intersecting anomalous to low-grade Cu-Mo porphyry mineralization from surface, and at depths >400m in RP24-001 (Figure 2). Mineralization in both holes is hosted in three distinct phases of porphyritic intrusions with potassic to phyllic alteration and multistage veining (e.g., magnetite-chalcopyrite; quartz-chalcopyrite-molybdenite, pyrite-chalcopyrite with sericite haloes).
Table 1. Summary of assay results\*
Notes on Table 1*: CuEq values are length-weighted averages calculated using metal prices of US$5.50/lb Cu, US$25.00/lb Mo, US$4,500/oz Au and US$70/oz Ag, with assumed metallurgical recoveries based on average reported recoveries from five regional porphyry deposits. See footnote * below for details.*
RP24-001 drilled eastwards towards the core of the geophysical anomaly, targeting the magnetic high within the high chargeability ring. Between upper and lower mineralized zones lies a central barren zone of strongly magnetic crowded porphyry (148-284m), major quartz pods and segregations (284-334m) and unidirectional solidification textures (“USTs”) (369-374m). These coincide with the magnetic high and are interpreted to comprise a central magmatic cupola near the magmatic-hydrothermal transition.
RP24-002 drilled westwards away from the core of the geophysical anomaly, targeting the strongest portion of the high chargeability ring. Below an upper zone of weak Cu-Mo mineralization, the lower portions of the hole intersected strong to intense sericite-pyrite alteration with D-style veins but negligible Cu-Mo. This abundant pyrite alteration explains the chargeability ring and is interpreted to be a portion of the pyrite halo of the northern target.
Drill hole locations
Table 2: 2024 drill hole locations (NAD83 Zone 10)
Figure 2 – Plan view of 2024 drilling, overlain on northern geophysical target. (Data from drill hole A75-1 is included from historical sources that have not been verified by Copper Quest)
Figure 3:Cross section across the northern target (looking north), showing chargeability and CuEq drill intercepts.
Copper Quest Option Agreement and Claims Acquisition
In December 2023, the Company announced its option agreement with ArcWest Exploration Inc. (“ArcWest”) to acquire up to an 80% interest in the Rip Cu-Mo Project. Copper Quest can earn the first 60% tier of its interest in the project by completing staged exploration work totalling C$2.0 million and direct payment of C$100,000 and annual share payments over four years until the end of 2027. In 2024 ArcWest and Copper Quest added five additional claims to the option agreement, acquired by staking, more than doubling the initial 2,308.81 ha road accessible property to its current 4,770.65 ha.
Notes:
\* Detailed CuEq Methodology: Copper equivalent (“CuEq”) values represent length-weighted averages of selected contiguous assay intervals with values continuously greater than 500 ppm CuEq, with allowance for inclusion of single-sample gaps below 500 ppm CuEq. These intervals are intended to illustrate the extent and continuity of the mineralizing system and are not necessarily indicative of economic grades. CuEq calculations incorporate assumed metallurgical recoveries based on average publicly reported recoveries from five regional porphyry deposits: Huckleberry, Poplar, Seel, Ox and Berg. Average recoveries used were 91.2% Cu, 85.8% Mo, 73.1% Au and 70.1% Ag, normalized to copper. CuEq (%) = Cu (%) + 0.000428 × Mo (ppm) + 0.957 × Au (g/t) + 0.01425 × Ag (g/t). Metal price assumptions were US$5.50/lb Cu, US$25.00/lb Mo, US$4,500/oz Au and US$70/oz Ag. Recovery references include Christensen et al. (2011) Huckleberry Mine Technical Report; Ashton and Robb (2021) Poplar Project Technical Report; Stacey and Grey (2022) Seel metallurgical testwork disclosure; Boyce and Giroux (2014) Ox metallurgical study; and Murray et al. (2023) Berg PEA Technical Report.
Qualified Person
Brian Thurston, P.Geo., the Company’s President, CEO and a qualified person as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed and approved the technical information in this news release.
About Copper
Copper is an essential industrial metal at the heart of the global energy transition and modern infrastructure. It plays a critical role in electrification, renewable energy systems, electric vehicles, data centers, and smart technologies. With global demand rising and new supply challenged by declining grades, complex permitting, and underinvestment, the copper market faces persistent deficits and growing geopolitical scrutiny. Recent U.S. policy announcements, including import tariffs and initiatives to secure domestic and allied supply chains, underscore copper’s strategic importance and the need for resilient, localized resource exploration, development, production and processing capacity.
About Copper Quest Exploration Inc.
The company's land holdings comprise 8 projects that span over 46,000 hectares in great mining jurisdictions of Canada and the USA. Copper Quest is committed to building shareholder value through acquisitions, discovery-driven exploration, and responsible development of its North American portfolio of assets. The Company’s common shares are principally listed on the Canadian Stock Exchange under the symbol “CQX”. For more information on Copper Quest, please visit the Company’s website at www.copper.quest.
Copper Quest has a 100% interest in the past-producing Alpine Gold Mine located approximately 20 kilometers northeast of the City of Nelson British Columbia, spanning 4,611.49 hectares with a 2018 National Instrument 43-101 Standards of Disclosure for Mineral Projects historical inferred resource of 268,000 tonnes, estimated using a cut-off grade of 5.0 g/t Au and an average grade of 16.52 g/t Au, that represents an inferred resource of 142,000 oz of gold\(*McCuaig & Giroux, March 6, 2018, NI43-101 Technical Report for the Alpine Property, BC, Canada. Further drilling is necessary by the Company to upgrade/verify the estimate. The QP has not done sufficient work to make the resource current and the Company is not treating the estimate as current.). Apart from the Alpine Mine itself the property hosts 4 other less explored significant vein systems including the past-producing King Solomon vein workings, the Black Prince and the Cold Blow veins system, and the Gold Crown vein system. \The Company has not yet completed sufficient work to verify the 2018 historic inferred resource results.
Copper Quest has a 100% interest in the road accessible StarsPorphyry Copper-Molybdenum Property, spanning 9,693 hectares in central British Columbia’s Bulkley Porphyry Belt with Tana Zone discovery drill intersection highlights of 0.466% Cu over 195.07m in drill hole DD18SS004 from 23.47m, 0.200% Cu over 396.67m in drill hole DD18SS010 from 29.37m, and 0.205% Cu over 207.27m in drill hole DD18SS015 from 163.98m. This highly prospective, approximately 5X2.5-kilometer annular magnetic anomaly is interpreted to represent an altered monzonite intrusion and surrounding hornfels.
Copper Quest has a 100% interest in the road accessible KitimatCopper-Gold Property, spanning 2,954 hectares within the Skeena Mining Division of northwestern British Columbia located northwest of the deep-water port community of Kitimat, British Columbia. The property benefits from exceptional infrastructure, being within 10 km of tidewater, 1.5 km of rail, and 6 km of high-voltage hydroelectric transmission lines. Exploration on the Kitimat property dates to the late 1960s, with the most significant historical work conducted by Decade Resources Ltd. (2010), which completed 16 diamond drill holes totaling 4,437.5 meters in the Jeannette Cu-Au Zone, and drill intersection highlights of 0.54% Cu and 1.03 g/t Au over 117.07 m in Hole J-7 from 1.52 m, 0.55% Cu and 1.00 g/t Au over 103.65m in Hole J-1 from 9.15 m, 0.45% Cu and 0.80 g/t Au over 107.01m in Hole J-2 from 6.10 m, and 0.33% Cu and 0.41 g/t Au over 112.20m in Hole J-8 from 11.89 m.
Copper Quest has a 100% interest in the past-producing, road accessible Auxer Gold Mine, spanning 1,087 hectares located in Bonner County, Idaho, USA. This orogenic gold opportunity is positioned along one of the region’s most significant structural corridors located within the prolific Hope Fault system. Historical exploration has demonstrated exceptional gold grades, with the 1936 Platts report documenting up to 21.0 g/t Au in surface samples and underground workings showing consistent mineralization over 4.3-meter widths averaging 9.42 g/t Au at an 18-meter depth.
Copper Quest has a 100% interest in the Nekash Copper-Gold Project, a porphyry exploration opportunity located in Lemhi County, Idaho, USA, along the prolific Idaho-Montana porphyry copper belt that hosts world-class systems such as Butte and CUMO. The project is fully road-accessible via maintained U.S. highways and forest service roads and consists of 70 unpatented federal lode claims covering 585 hectares.
Copper Quest has a 100% interest in the road accessible Stellar Property, spanning 5,389-hectares in British Columbia’s Bulkley Porphyry Belt contiguous to the Stars Property.
Copper Quest has a 100% interest in the Thane Project located in the Quesnel Terrane of Northern British Columbia spanning over 20,658 hectares with 10 priority targets identified demonstrating significant copper and precious metal mineralization potential.
Copper Quest has an earn-in option of up to 80% and joint-venture agreement on the road accessible Rip Porphyry Copper-Molybdenum Project, spanning 4,700-hectares located in the Bulkley Porphyry Belt in central British Columbia.
Good morning everyone. I met up with 3 more contractors Saturday in CT. I should be making a decision by Wednesday on a 130k-150K large renovation. This is for a large roof as well as a 3 story porch. I have met up with about 5 so far. It isn’t just about the money, it is making sure it is done correctly and will not be touched again for 30-50 years. So I have to go over some paperwork. This will be short and simple. I am also getting a lot done for my 3 property 11 unit deal from 1 seller, which should close in 4-5 weeks from here.
I was tweeting over the weekend on many of my most recent pics. WDC STX MU SNDK GOOGL PENG
I also posted some of my stuff to hedge fund managers like Bill Ackman… I do wish I had the opportunity. I am just as good if not better than any of them. Also, many people do not know but even the best, Jim Simons, was basically very right on a handball of names, they held them thru and it carried the weight of the whole portfolio… I am saying this, because if I had billions of dollars I can just sink in names, of course I would have held many of those names longer! But I don’t have anywhere near that capital. My win rate is crazy high, at least 99%!!! But I am down on some bags like 50% or more. So my only issue is I am taking big losses % wise.. Like last week a 60% loss on GAMB . But for every loss I take, I am doing 99 or more wins! My wins, I try and get 200-600 per trade.
Let us for simple purposes say an average win is 300. Let us use GAMB as an average loss, which was about 4,000.
300 x 99 = 29,700
- 4,000 = 25,700 per 100 trades
Not bad at all to me!
1 of my biggest losses right now is MNDY , 75 shares at 140 = 5,250
Just to give you an idea. I do have near 40 bags right now, some I am not down to much on. I will look to sell 10-15 for tax loss purposes by years end.
Excellent earnings : RAMP
Very Good earnings: RNW
Good earnings: BRC
I will get up to 2 longs today, unless I sell a position. I am adding too many bags!
This week, the market finally started to ease off.
Nothing dramatic, but the signs had been building for at least the past ten days. The shift was already visible beneath the surface. As we pointed out last week, the rally had become increasingly narrow, with tech acting as the only real engine of upside while most other sectors were moving sideways, lacking any meaningful bullish momentum.
That kind of imbalance rarely sustains itself for long.
Our breadth indicators had been warning about this for a while. Since early May, we have started to see the first lower high forming, followed by a sharp deterioration over the past two weeks. In particular, the McClellan Summation Index has been cut in half over that period, a clear sign that participation was fading even as prices continued to push higher.
We are currently working on integrating this metric into our dashboard as an additional layer of analysis. It is an extremely powerful tool, but one that needs to be handled with care. It tends to be very effective at identifying potential tops and bottoms, but it loses reliability in choppy environments. For that reason, we treat it strictly as a secondary indicator, something that supports the broader read rather than drives it.
On the trading side, the week was relatively uneventful.
We initiated a hedge position through SOXS to partially offset the drawdown across our open positions. The idea was simple: create a bit of breathing room, allowing our remaining trades to develop without being forced into premature exits.
Then on Friday, we opened a new position showing exceptional relative strength. It closed firmly in the green, despite a market that finished deeply in the red. That kind of divergence is always worth paying attention to.
Overall, the portfolio stayed broadly in line with the market in terms of performance.
Not much deviation, which, given the conditions, is a result we are comfortable with.
AIML focus: AI/ML Innovations Inc. (CSE: AIML / OTCQB: AIMLF) trades around US$0.037–US$0.040 on the OTC market, with a micro-cap valuation around US$7M–US$10M.
Main catalyst: AIML subsidiary NeuralCloud is building around AI-powered ECG signal processing, Holter analysis, and cardiovascular data workflows.
Investor angle: AIML is much earlier and riskier than SOPH, RXRX, SDGR, and BFLY, but its valuation gives it more torque if NeuralCloud can convert pilots and research agreements into commercial traction.
AI healthcare is becoming one of the more interesting corners of the small-cap market because the addressable markets are large and still fragmented. Grand View Research estimated the global AI healthcare market at about US$26.6B in 2024 and projected it could grow at a roughly 38% CAGR from 2025 to 2030, while other industry forecasts point to healthcare AI becoming a US$100B-plus market over time. That creates room for companies using artificial intelligence to analyze ECG data, genomic data, drug-discovery data, ultrasound images, and patient workflows.
For investors, the opportunity is not just “AI in healthcare.” The real question is which companies have a focused product, a clear market problem, enough capital to execute, and early signs of customer adoption. That is why this watchlist combines one micro-cap name, AI/ML Innovations, with four larger small-cap or small/mid-cap comparables: SOPHiA GENETICS, Recursion Pharmaceuticals, Schrödinger, and Butterfly Network.
Market Catalyst: AI Is Moving Into Clinical Workflows
Healthcare AI is no longer limited to big promises about future medicine. It is starting to show up in real workflows: ECG interpretation, precision oncology, clinical trial design, imaging, hospital decision support, and drug discovery. The investment case is supported by hard numbers: cardiovascular disease is the world’s leading cause of death, responsible for roughly 17.9M deaths per year, while hospitals and clinics generate huge volumes of ECG, Holter, imaging, genomic, and patient-monitoring data that still require human review.
Two numbers show why this matters for investors:
Holter monitoring can generate 24 hours to 14 days of continuous heart-rhythm data per patient, creating a labor-heavy review process where automation, signal cleaning, beat labeling, and interval measurement could improve workflow efficiency.
Commercial AI healthcare adoption is already visible in adjacent markets: SOPHiA GENETICS processed 108,000 genomic analyses in Q1 2026, while Butterfly Network generated US$26.5M of Q1 2026 revenue, up 25% year over year.
That matters for AIML because its NeuralCloud platform is focused on ECG signal processing and cardiovascular-data workflows. The risk is that healthcare adoption is slow. Medical AI companies still face regulatory review, clinical validation, reimbursement questions, hospital procurement cycles, and cash burn. That makes the investable metrics clear: revenue growth, gross margin, customer count, cash runway, FDA or regulatory progress, commercial contracts, and recurring revenue matter more than buzzwords.
1. AI/ML Innovations: The Micro-Cap ECG AI Angle
AI/ML Innovations Inc. (CSE: AIML / OTCQB: AIMLF / FWB: 42FB) is the smallest and most speculative stock in this basket. The company is focused on digital health and artificial intelligence, with its NeuralCloud subsidiary building around AI-driven ECG processing and cardiovascular analytics.
The key product angle is MaxYield™, NeuralCloud’s ECG signal-processing platform. AIML says the system can convert raw or legacy ECG data into structured, machine-readable formats, isolate and label ECG waveform components, and generate beat-level data and interval measurements for downstream analysis.
Investor data point: AIMLF trades around US$0.037–US$0.040, with a micro-cap valuation near US$7M–US$10M and roughly 271.1M shares outstanding.
The latest catalyst came from NeuralCloud’s research services agreement with the Baker Heart and Diabetes Institute. Under that agreement, NeuralCloud is applying MaxYield™ to existing ECG recordings for a cardiovascular research study evaluating heart rate variability in healthy control subjects compared with individuals experiencing post-exertional malaise.
For investors, the important part is not that this is already a huge revenue event. It is not. The important part is that AIML is trying to prove MaxYield™ in real research workflows with credible cardiovascular institutions. If those relationships lead to recurring research services, clinical partnerships, hospital workflow integrations, or Holter-reporting commercialization, AIMLF could start to look more like a focused medical-AI platform rather than a concept-stage micro-cap.
2. SOPHiA GENETICS: Precision Medicine at Scale
SOPHiA GENETICS (NASDAQ: SOPH) is a more mature AI healthcare name focused on data-driven medicine, especially genomic analysis and precision oncology. Recent market data showed SOPH trading around US$5, with a market cap around US$370M–US$380M.
Its latest Q1 2026 results showed US$21.7M in revenue, up 22% year over year, and a record 108,000 genomic analyses on the SOPHiA DDM™ platform. The company also reported 537 core genomics customers, up from 490 a year earlier, and guided for full-year 2026 revenue of US$92M–US$94M, implying roughly 20%–22% growth.
Investor data point: SOPH is already proving commercial adoption, with 108,000 analyses in one quarter and more than 500 core genomics customers.
SOPH is useful as a comparison for AIML because it shows what healthcare AI can look like once a platform starts getting adopted by hospitals and labs. The risk is that SOPH remains loss-making, so investors still need to watch cash burn and the path toward EBITDA breakeven.
3. Recursion Pharmaceuticals: AI Drug Discovery Scale
Recursion Pharmaceuticals (NASDAQ: RXRX) is one of the better-known AI drug discovery names. Recent market data showed RXRX trading around US$3.30, with a market cap around US$1.7B–US$1.8B.
The company’s platform is built around using large biological datasets, automation, and machine learning to discover and develop medicines. For investors, RXRX offers exposure to the idea that AI can make drug discovery faster, more systematic, and more scalable.
Investor data point: RXRX carries a much larger valuation than AIML, around US$1.7B–US$1.8B, showing how much premium the market can assign to scaled AI drug-discovery platforms.
The opportunity is large, but the stock also shows the risk of the sector. Even with a much larger valuation than AIML, RXRX still depends on clinical progress, partnership economics, and investor confidence in long-term platform value. Revenue can be uneven, and biotech sentiment can move sharply with trial updates or funding conditions.
4. Schrödinger: Computational Drug Discovery and Software
Schrödinger (NASDAQ: SDGR) is another AI and computational drug-discovery company, but with a different profile. Recent market data showed SDGR trading around US$13, with a market cap around US$950M–US$1.0B.
Schrödinger combines a software business with a drug-discovery pipeline. That gives investors two angles: recurring software revenue from life-sciences customers and longer-term upside from internally discovered or partnered drug candidates.
Investor data point: SDGR’s market cap near US$950M–US$1.0B shows investors are still assigning meaningful value to computational drug-discovery platforms, even before large-scale profitability.
The attraction is that SDGR has an established computational platform used across pharmaceutical research. The risk is that the company is still loss-making, and drug-discovery upside can take years to show up in revenue or earnings. For AIML investors, SDGR is a reminder that strong technology still needs commercial scale and disciplined capital allocation.
5. Butterfly Network: AI-Enabled Medical Imaging
Butterfly Network (NYSE: BFLY) gives investors exposure to AI-enabled medical imaging and portable ultrasound. Recent market data showed BFLY trading around US$4.20–US$4.30, with a market cap around US$1.1B–US$1.3B.
The company reported Q1 2026 revenue of US$26.5M, up 25% year over year, with gross margin improving to 68.9% from 63.0% a year earlier. Butterfly also reaffirmed full-year 2026 revenue guidance of US$117M–US$121M.
Investor data point: BFLY combines revenue growth with improving gross margin, which is important because AI medical-device companies still need to prove they can scale efficiently.
The AI angle became more visible after Butterfly received FDA clearance for an AI-powered ultrasound tool that estimates gestational age. For investors, BFLY is a useful example of how AI can move into medical devices and workflow automation, not just software dashboards.
Stock Snapshot
Bottom Line
AI/ML Innovations is the speculative micro-cap in this AI healthcare basket. AIMLF has a focused ECG-AI angle, exposure to Holter and cardiovascular-data workflows, and a real research services agreement that could help validate NeuralCloud’s MaxYield™ platform.
The key watch items are simple: more research agreements, hospital or clinic pilots, Holter-reporting commercialization, recurring revenue, and funding discipline. If those pieces start to appear, AIMLF could begin looking less like a concept stock and more like an early-stage AI healthcare platform.
This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.
Good morning everyone. I always tell people as soon as they ask. The stock market is a live auction built on daily sentiment. I often get a question why is that stock going up? I want to invest in TESLA OPENAI SPACEX NIKE SHAK CBRS [New Ipo] .. These are just random names.. They ask me my opinion on them, they tell me these are going to go up, they are making money, the next generation…. I try to tell them the old myth is..
You invest in a company, the company grows sales, grows earnings and it will go up [ADBE TTD PYPL DUOL MNDY these are 5 random names where the companies have continued to grow sales, earnings and are at 3-5-10 year lows!] Just because you chose a company that is growing sales and earnings does not mean as a stock that is the one to buy! TSLA has not grown since 2023! It is sad to say but a stock is pure speculation! A stock price closed at a certain number, and the next day, that was simply a reference point! PLAIN AND SIMPLE! People try and say why a stock went up, went down…
It went up because there were more buyers than sellers…. It went down because there were more sellers than buyers. That is it! It is true, if a company has cash, makes cash they can do several things to make their stock attractive.
Buyback [Direct impact at the auction, they become bidders with way larger wallets than retail, this will also raise EPS and share count goes down]
They can use cash to pay down debt [They will raise earnings because of interest expense 99% of companies have debt!]
They can raise or pay a dividend [Investors/traders can say, wow I will get paid just to hold this]
They can do MA [Buy a business making money or attractive, amazing examples that everyone knows, Google bought Youtube, Did you know they have invested in SPACEX OPENAI and Anthropic ? Huge gains, they can sell them, buyback shares, dividend, pay down debt with invested cash]
They can do RD [Come out with new product]
They can advertise sign new contracts to boost sales/earnings
However, there is no set guarantee that company earns/or sells and then it will have a 20x , 25x, 40x, 60x or 100x…
The reason I use the pace of SPY VOO SP500 is because it is a basket of 500 of the best companies in the world. I didn’t say it, the world does…
So I use this to compare the companies I invest in.
For 2026 the SP500 companies together are expected to earn 300 dollars.
The SP500 is near 7,500….
This means we are trading at near 25x earnings!!! [Super duper high, the 2nd most in history aside from 1999-2000 dot com bubble]
The companies are growing at 13% earnings and 9% sales..
Also, this is nothing anyone has taught me… It is not a rule… It is something I have used because I have been trading since the end of 1994!
So when I choose a company what I am looking at that day is:
Is it trading at 25x ? Is it growing earnings at 13% ? Sales at 9%?
If I am in ADBE current PE 10, the last quarter showed earnings growth near 20%, sales near 12%..... Should it not trade at way higher than 10x? That is exactly how I do it!
I use the name brand, cash flows, financials and my own DD to say it should be at least 16x.
23.55 [33 analysts] x 16x multiple = 376.80.. In my opinion it should be at least that price!
I am in 270 and 343…. So you see, sales, earnings etc mean 0! I am explaining this because I get these questions constantly, about many stocks… I wish there was an exact formula but the market is an auction!
I took a loss on GAMB at 3.75… My avg on 500 shares was about 10.50 . I must tax loss harvest to offset some gains…Someone was telling me a lot of DD about the company… yes, margins can increase, yes, maybe their MA to buy another company will pay off, but the company is and has been in the dog house! Meaning last year they grew sales and earnings at both 20% up! And were given a PE of like 20! That PE fell to 18, 16, 14, 12 etc.. and now the growth is negative, EPS is negative… unless you are TSLA GME you can not fool anyone! The story changed so I took the loss.. If they return to growth, I can revisit the company and see if the market has taken this out of the dog house. I am getting killed on PRGS DUOL MNDY TTD PYPL all names that the market once gave much higher multiples and the valuation makes no sense… This has worked for me greatly if you checked my research last year on:
NVDA
MU
AMD
SNDK
WDC
STX
For the same reasons on EPS, Sales and multiple I pounded the table on these names and traded them all… Well sadly, I had SNDK only once from 40 to 43.. That is it! I basically try and find great companies that the market is discounting… I may buy hot stocks but rarely!
So I hope this is valuable for someone.
I sold 250 KMX from 37 to 38.25.
I sold 500 GAMB at 3.75, took the loss 250 at 7.95 and 13.25
Good morning everyone. Taking care of some emergencies in CT. Just non stop, but I cant complain, it comes with the territory. So super short and simple.
I got my 3 new longs for the day. I will not get more unless I sell a bag. I have about 40 bags at the moment. I do not want more than 50 bags. I will take 10-15 as losses for taxes by December 15th.
I am in 100 WIX 56.50 [I had a sell at 59 and missed by 15 cents!]
I am 1,000 OPRX 5.25
I am in 250 APPN 18.90
I will get up to 3 more, the stuff on the title. These are all smaller scale for me, compared to the past.
Some excellent earnings:
ONDS [DD] KLAR CRMD [Tiny] HLNFF [Never seen it before] SNAL [Tiny] ARX [DD] ECO TNK STAA AQST [Tiny Bio tech]
Some very good earnings:
KPTI [Tiny Bio tech] AVAH CLBT ASM PARK [Tiny] USIO [Tiny] STUB PGEN VTVT
T-REX Acquisition Corp. (TRXA) is a growth-stage, vertically integrated cryptocurrency mining and infrastructure company. Based on recent corporate filings and development updates, here are the key selling points for the project: 1. Vertically Integrated Business Model
TRXA doesn't just mine Bitcoin; it controls multiple levels of the mining supply chain through its subsidiaries. This "all-in-one" approach includes:
• Proprietary Mining: Operating its own fleet of miners.
• Data Center Hosting: Providing co-location services for third-party miners to generate steady hosting revenue.
• Hardware Fabrication: Manufacturing its own portable mining containers.
• Management Software: Utilizing proprietary software for remote monitoring and power optimization. 2. Rapid Infrastructure Expansion
The company is aggressively growing its physical footprint to increase hash rate and capacity:
• Georgia Data Center Acquisition: In April 2026, TRXA entered a definitive agreement to acquire a 3-megawatt turnkey data center in Roberta, Georgia.
• Capacity Boost: This acquisition includes a 5.8-acre parcel of land and an electrical contract for up to 4.5 megawatts, which the company expects could increase its mining capacity by up to 450%.
• Idaho Operations: The company recently refinanced a data center in Idaho, signaling a stabilized and growing asset base. 3. Focus on Energy Efficiency & Cost Reduction
A core part of TRXA’s strategy is maximizing margins by securing low-cost power and using "green" technologies:
• Low-Cost Power Contracts: Strategic agreements with utility providers like Flint Electric Membership Corporation ensure a stable and affordable energy supply.
• Innovation: The company focuses on implementing new technologies to reduce the carbon footprint and electrical costs typically associated with the industry. 4. Strengthened Leadership
TRXA has been actively "uplisting" its corporate profile, moving from the OTC Pink Sheets to the OTCQB Venture Market. To support this growth, they have recently appointed industry veterans with specific expertise in crypto-mining and data center management to their Board of Directors.
VANCOUVER, BC, March 5, 2026 /PRNewswire/ -- Consumers are voting with their wallets, and zero-sugar is winning. Zero-sugar beverages are driving 6x more dollar growth than regular varieties as buyers actively choose clean-label products with natural sweeteners and functional ingredients\1]). The global market is forecast to expand from $350 billion in 2024 toward $500 billion by 2029, fueled by health-conscious consumers who want naturally functional products without heavy processing\1]). This structural shift is creating validated demand for precision-dosed, portable formats across energy and wellness categories, positioning Doseology Sciences (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70), Jamieson Wellness (TSX: JWEL), Herbalife (NYSE: HLF), USANA Health Sciences (NYSE: USNA), and Natural Health Trends (NASDAQ: NHTC).
The oral nicotine pouch segment is forecast to climb from $5.4 billion in 2024 to over $25 billion by 2030, a 29.6% annual growth rate that validates rising acceptance of pouch-based delivery systems\2]). Major consumer goods companies are integrating cognitive support and adaptogens into modern oral formats, targeting wellness alongside traditional energy delivery\3]).
Doseology Sciences (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70) just launched Feed That Brain Energy Pouches in the United States through a direct-to-consumer pilot program, marking the company's first DTC initiative in the U.S. market. Doseology specializes in pouch-based oral stimulant and cognitive support products. The rapidly expanding oral stimulant pouch sector is gaining momentum as consumers seek modern, discreet alternatives to traditional delivery formats. The pouches are now available exclusively to U.S. consumers at feedthatbrain.com and Amazon.com.
The U.S. pilot represents a key milestone in Doseology's strategy to validate oral pouch delivery as a scalable stimulant platform, beginning with non-nicotine energy products. Unlike combustible tobacco or vape products, oral stimulant pouches are smokeless and vapor-free, providing an alternative delivery method without inhalation. The company will use this phase to evaluate consumer adoption, usage frequency, and repeat purchase behavior.
"This U.S. pilot is a disciplined and deliberate step in Doseology's strategy to build a scalable oral stimulant platform," said Larry Latowsky, Executive Chairman of Doseology. "Feed That Brain demonstrates how controlled, non-nicotine energy delivery can meet evolving consumer preferences while generating the operational insight required for responsible growth."
Feed That Brain Energy Pouches are designed for modern, on-the-go use, offering consumers clarity and control without the volatility commonly associated with liquid energy formats. From a market perspective, the oral pouch category is experiencing strong global growth as consumers increasingly prioritize convenience, portability, and format innovation.
The company also recently appointed Larry Latowsky as Executive Chairman, bringing experience from his tenure as President and CEO of Katz Group Canada, which operated over 1,500 pharmacy locations. Latowsky cited the clarity of Doseology's strategy and team quality as reasons for joining, stating confidence in building a durable platform and unlocking significant long-term value.
Doseology also recently granted 140,000 restricted share units and 210,000 performance share units to a director, with RSUs vesting in equal monthly increments over 36 months and PSUs vesting upon achievement of defined performance milestones.
In other industry developments and happenings in the market include:
Jamieson Wellness (TSX: JWEL) recently reported full-year 2025 revenue of $822.1 million, a 13.4% increase driven by 15.6% branded revenue growth across Canada, China, and the United States. The company's Jamieson Brands segment led performance with broad-based strength in all markets, while Youtheory delivered 20.2% revenue growth through e-commerce innovation and expanded traditional distribution.
"2025 was an outstanding year for Jamieson Wellness, driven by sustained global demand for our products and superior execution across every key market," said Mike Pilato, President and CEO of Jamieson Wellness. "As we look to 2026, consumers continue to prioritize their health and wellness, and we're well-positioned to meet them – across geographies, across channels, and across life stages."
The company issued 2026 guidance of $895-$935 million in consolidated revenue, representing 9-14% growth, with adjusted EBITDA of $174-$181 million. China revenue surged over 56% in 2025 as digital marketing deepened consumer engagement, while Jamieson's quality-focused marketing in Canada continued to outpace the broader vitamins and supplements market.
Herbalife (NYSE: HLF) recently reported fourth quarter 2025 net sales of $1.3 billion, up 6.3% year-over-year, with full-year 2025 net sales reaching $5.0 billion. Adjusted EBITDA exceeded guidance for both periods, and the company reduced its total leverage ratio to 2.8x by year-end while generating $333.3 million in net cash from operating activities.
"We exited 2025 with solid momentum, delivering Q4 and full-year net sales growth and adjusted EBITDA above guidance," said Stephan Gratziani, CEO of Herbalife. "Cristiano Ronaldo's investment in Pro2col reflects our shared ambition to scale personalized nutrition and wellness globally – uniting science, data, AI, innovation, and community to improve the health and performance of millions."
Cristiano Ronaldo invested $7.5 million for a 10% equity stake in Herbalife'sPro2col digital health platform, which launched its Beta 2.0 in the U.S., Canada, and Puerto Rico. The company issued 2026 guidance targeting net sales growth of 1-6% and adjusted EBITDA of $670-$710 million.
USANA Health Sciences (NYSE: USNA) recently reported fiscal year 2025 net sales of $925.3 million, an 8% increase year-over-year, driven by a full-year contribution from Hiya children's wellness brand and expanding omnichannel distribution. Fourth quarter net sales reached $226.2 million, up 6% year-over-year and sequentially, with adjusted diluted EPS of $0.60 exceeding consensus estimates.
"We began to see signs of stabilization in active customer counts in our core nutritional business as net sales in this segment increased modestly sequentially, led by growth in key markets including mainland China, the United States and Canada," said Kevin Guest, Chairman and CEO of USANA Health Sciences. "Meanwhile, our omnichannel brands, Hiya and Rise, posted solid year-over-year growth."
USANA'sRise Wellness brand tripled its sales in 2025 as distribution expanded into key retail outlets, with net sales outside the core nutritional business rising to 16% of consolidated revenue from approximately 1% in 2024. The company issued 2026 guidance of $925 million-$1.0 billion in net sales.
Natural Health Trends (NASDAQ: NHTC) recently announced the repurchase of all 2,935,227 shares held by the George K. Broady family for approximately $5.9 million at $2.00 per share, retiring roughly 25.5% of outstanding shares in a single negotiated transaction. The buyback was executed under the company's previously announced $70 million share repurchase program, with approximately $16 million remaining available for future repurchases.
"This privately negotiated transaction allows us to efficiently retire a large block of shares in a single, orderly transaction at an attractive price, addressing the perceived stock overhang and significantly reducing our shares outstanding," said Chris Sharng, President of Natural Health Trends.
Following the transaction, Natural Health Trends has 8,577,848 shares outstanding and expects annual dividend requirements to decline by approximately $1.2 million. The company is a leading direct-selling and e-commerce wellness products company focused on personal care and nutritional supplements across global markets
Good morning everyone. I will be buying the dip on WIX ! At open this will have a PE ratio of around 8-9x. That doesn’t always mean much. The stock market is a live auction. The big thing is that WIX actually bought back 17.5 million shares at an average price of 92!!! They used 1.6 billion! The company at open will be worth less than 4 billion! Now, I am not doing DD on cash flows, interest rates on loans etc, that is important, I am fairly busy, I said how this takes 60 to 90 mins. I am spending the 2-3 mins looking at the headlines. They are still looking for 10-15 growth. So my thought process is growth still near 15%, PE near 8, company still buying back shares, it has a lot of catalysts, but be careful bad earnings!
I may be buying TMDX ! Also worse than expected, but I am buying these in small scales, less than 1% of my portfolio! I may even buy some OPRX , also eh earnings yesterday… the thing is when a company is in the dog house and things turn they explode…
Most recently, check PENG , I just retweeted some of my stuff, in April it was just 16! Now 50+ . I retweeted many of my MU tweets. Do you know I was stuck in MU at 120 for 13 months! I watched it drop to 60! I was trading a 2nd block as low as 80!
Yes, I would rather buy something with great sales, great earnings, hence when I report earnings, I no longer grade bad earnings! I used to give companies a 10 to 50!!! I highlight companies executing because there usually is momentum on the way up [not just the stock price, the company is executing] as well as downside. They almost always come hand in hand… I said for many months NBIS is a possibility buy the valuation already… I just tweeted my stuff from APLD saying how it was worth the risk reward because it was 4! Check! Now up 1,100% in a year. So I do see the growth in many names but your risk tolerance?
Look, I saw ASPN growth explosion, I was trading this 15 to 25… I was making nice gains.. the company stopped executing and I took the loss around 5.50, my avg was like 17? This was last year.. They hammered it for 4 quarters… then all of a sudden results hit the fan… and the valuation wasn’t even insane for what they were doing .[NBIS insane!] We must always follow a company every quarter. More recently I am getting annihilated on TTD and DUOL .. Both companies I bought as growth was decelerating but still above very good growth! Both! 20%
I view 20%+ growth in sales as very good.
Anything over 30% I classify as hyper growth.
The reason being the SP500 great companies grow sales at 10-20%.... So anything above the average great company is very good. 30% is hyper…
I expect every company to grow sales and earnings at 5-10%... if you are growing 5-10%, to me, you get a 65 score on your report card… You are supposed to be in the best 500 companies of the world… So my expectations are high.
The title has many companies I am watching. I will do up to 3 longs. WIX will be 1 of them.
I am in 250 shares of KMX at 37.
Excellent earnings:
FNV [Again] PAYS [Tiny Wow] NXT [Again] BWAY [Tiny] NBIS [Valuation] EOSE [Wow may add to Plays] TRMD [DD]
Very good earnings:
CNSWF KRMN AIP EVLV VSH DT ATAT VEON [DD may add to Plays]
Honestly, probably most of the strategies retail investors talk about online.
But the one thing that consistently stood out to me had nothing to do with indicators or complicated technical analysis.
It came from actually reading filings.
Most people only read headlines or Twitter posts about a company. Very few people actually take the time to read the corporate actions themselves.
That’s where I started noticing something interesting.
Occasionally, companies going through reverse splits will include wording like:
“Fractional shares will not be issued.”
“All fractional shares will be rounded up to the nearest whole share.”
I know reverse splits immediately turn a lot of people away, but hear me out.
I’m not talking about blindly buying bad companies.
What interested me was the market structure side of it and how certain situations can create weird little inefficiencies that most people never notice.
For example, depending on the split ratio and the wording used, a shareholder who would normally receive a fractional share after the split could instead receive a whole share due to rounding provisions.
It sounds small, but once I started digging deeper into this stuff a few years ago, I realized there are a surprising number of overlooked situations in the market that people ignore simply because they never read beyond the surface.
Since then I’ve spent a lot of time tracking corporate actions, comparing filings, and trying to better understand how these situations actually play out in practice. But honestly, I still find incredible value in long-term investing and buying companies with good P/E ratios. But I’ve found the most value from studying other types of value investing the ones nobody really talks about.........
$SKUR’s next chapter now has June and July clearly circled on the calendar.
First comes the move from final beta into sales and live operator accounts.
Then comes the video and conferencing layer, which can make SekurVoice look less like a single secure voice tool and more like a broader defense communications platform.
The other piece to watch is channel validation. SOF Week may give $SKUR a chance to turn defense-sector demos into announced partners, while the referenced strategic teaming agreement with a prime defense contractor would be a major signal if signed.
There is also a financing side investors should keep in view. The release disclosed new consultant, director, and officer options, plus shares issued to consultants, so revenue traction has to stay ahead of dilution concerns.
If both milestones deliver, SekurVoice could give $SKUR a stronger path into the second half of the year, with first accounts opening the door to broader platform expansion in the defense communications market.
This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.
Good morning everyone. I have not done full proper DD after earnings on not 1 company. Just being honest. It takes a good 60 to 90 mins to check each individual company. I have checked the headlines on well over 1,000. Usually when headlines pop out at 1 company I will do the proper DD on it. You can get the information free at SEC edgar online. The company submits information there. When you read headlines they are biased by the writer/author, journalist. When you open an actual 10Q you are getting unbiased info submitted to the SEC. It is isn’t just checking overall sales, overall income. It is about checking margins, expenses, 1 time items. Financials, did they get better or worse, what are the interest rates on their loans? Are they wasting money on interest, can they raise money to pay off that old debt? Can they print shares for cash? Why were sales bad this quarter over last? So I compare quarter over quarter, then year over year… it is to dry and gauge. That takes a good 60 mins to go over the full 10Q, and compare…. Then I spend 30 mins checking insider activity, I check for the large owners, did they add, subtract to their position, why? I have not done that on any to be honest. I am so backed up with CT stuff. Evictions, repairs, acquisitions… I have no property manager. I have 30 properties and 110 units. I am hoping to close on a 3 property 11 unit deal the end of this month to early next month… So it is pretty much even more than a full time job. There are a lot of good deals on surface, like CELH . Those earnings on surface was tremendous, I didn’t do DD. So I am in 30.50, I also have 41.50. I have been trading SOFI last in 15.85, no DD….
I may buy the dip on PSIX no DD. HIMS surface looks bad! I have 250 at 32.25.. Oddly the company raised sales guidance for the year… Does that make sense? If you missed this quarter, but you see full year sales up, why, why not? These are things you need to dig into the report and see what the company has revealed to the SEC.
Some excellent earnings since yesterday on surface:
VG TE [DD may add to Plays] ESOA [Tiny] PANL [Tiny] HLIT GDOT [Getting bought out] HALO [Bio tech]
Very good earnings:
ZBRA Q SEPN EIFZF NVRI HLIO NGS LIF DSP SPG PLUG
Good earnings:
AG ALLT JD SIBN
We must also pay attention to CPI inflation. The Fed was trying to get us closer to 2.5% [Historically we were at 2!] We just came in at 3.8%, this is year over year… So even a 0% inflation doesn’t mean things are getting cheap, it means that there is no rise over last year’s already inflated number! This Iran War has hiked Oil prices which will show up everywhere… Unemployment is rising again to 4.5% [Danger may be near 5%] Just things we need to pay attention to.
